Surmodics

Surmodics FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Surmodics (SRDX) as of Sep 26, 2026 is 28.11 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -494.53 % — a change of -105.68% (higher).

FCF Conversion

28.11 %

YoY

-105.68%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Surmodics is 2026 28.11 % . FCF Conversion Rate (FCF/EBITDA) of Surmodics was 2025 -494.53 % . It decreases by -105.68% higher compared to the previous year.

The Surmodics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
194.12 USD
Jan 1, 2018
-447.83 USD
Jan 1, 2019
16.99 USD
Jan 1, 2020
920.66 USD
Jan 1, 2021
215.01 USD
Jan 1, 2022
75.50 USD
Jan 1, 2023
-494.53 USD
Jan 1, 2024
28.11 USD
The Surmodics FCF Conversion history
YEARFCF ConversionYoY
28.11 %-105.68%
-494.53 %-754.97%
75.50 %-64.88%
215.01 %-76.65%
920.66 %+5,318.33%
16.99 %-103.79%
-447.83 %-330.70%
194.12 %+14.19%
169.99 %+73.91%
97.75 %-26.07%
132.22 %—
Access this data via the Eulerpool API

Surmodics Stock analysis

What does Surmodics do? Surmodics Inc is an American company specializing in medical technology, based in Eden Prairie, Minnesota. They focus on developing and commercializing technologies to improve disease diagnosis and treatment. The company offers a wide range of medical devices and solutions for various medical applications, including cardiology, radiology, oncology, ophthalmology, and pharmaceutical development. Surmodics operates in three main business areas: medical devices, hollow fiber technology, and bioactive coatings. Their products are designed to meet the specific needs of customers and medical applications. Surmodics has a strong global presence and has expanded through strategic acquisitions in recent years, particularly in the pharmaceutical development and hollow fiber technology sectors. Surmodics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Surmodics stock

FCF Conversion Rate (FCF/EBITDA) of Surmodics is 28.11 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Surmodics changed from -494.53 % to 28.11 %, representing a -105.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Surmodics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Surmodics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Surmodics

All Key Metrics — Surmodics